HIV 101: Core Principles of HIV Management for People Who Are Newly Diagnosed With HIV (On-Demand)

Assessment of Needs

A firm grasp of the basics of clinical care for patients with HIV is essential for practitioners in Ryan White HIV/AIDS-funded clinics and programs who are new to HIV care. In this webinar, experts in the field will describe the core principles of HIV management, including pathogenesis of HIV infection and mechanisms of action of antiretroviral drugs, as well as initiating antiretroviral therapy and primary care for people who are newly diagnosed with HIV. This webinar will also be useful to experienced clinicians who seek a review of these core principles.

Learning Objectives

On completion of this activity, learners will be able to:

• Describe the pathogenesis of HIV disease and the life cycle of HIV
• Conduct an initial assessment of a person newly diagnosed with HIV
• Initiate an appropriate initial antiretroviral therapy regimen in people with HIV according to their clinical presentation and preference
• Provide appropriate vaccinations for people with HIV, focusing on pneumococcus, hepatitis B, SARS-CoV-2, and mpox according to current guidelines put forth by the Centers for Disease Control and Prevention
• Maintain continuous monitoring for antiretroviral therapy success and for emergence of comorbid conditions, including cardiovascular disease, renal disease, frailty, etc

Registration

Who Should Attend

This program is designed for clinical decision-makers in Ryan White HIV/AIDS Program (RWHAP)-funded clinics and programs who are new to HIV care and those practitioners who are interested in a review. It is also relevant for registered nurses, pharmacists, and other health care professionals.

Please note: if you already have participated on the live webinar and have received CME credits, you will not receive additional credits from this activity.

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”

IAS–USA has identified and mitigated ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. All relevant financial relationships with ineligible companies have been mitigated among the planners and the presenter. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content.

COW Board

The financial relationships of the COW Board can be found here: https://www.iasusa.org/activities/cases-on-the-web/about-cows/cow-webinars-editorial-board/